Cambrex (NYSE: CBM) is one of 101 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Cambrex to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, institutional ownership, earnings and dividends.
This is a summary of current ratings and recommmendations for Cambrex and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Cambrex and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cambrex||$490.64 million||$81.67 million||16.20|
|Cambrex Competitors||$8.17 billion||$1.09 billion||155.65|
Cambrex’s competitors have higher revenue and earnings than Cambrex. Cambrex is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.5% of Cambrex shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Cambrex and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Cambrex has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Cambrex’s competitors have a beta of 34.16, suggesting that their average stock price is 3,316% more volatile than the S&P 500.
Cambrex competitors beat Cambrex on 7 of the 13 factors compared.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.